Agios leukemia drug demonstrates impressive response rate: study

Forty percent of patients, most with a particularly aggressive form of leukemia, responded to an experimental Agios Pharmaceuticals Inc drug, including several who experienced complete remission, according to data presented at a medical meeting on Friday. New data from the ongoing Phase I clinical trial appears to confirm the early promise seen with the Agios drug, AG-221. Patients in the study either had the aggressive bone marrow cancer acute myelogenous leukemia (AML), or the pre-leukemic blood disorder myelodysplastic syndrome (MDS).
Go to Source